Karus Therapeutics

About:

Karus is a pharmaceutical company focused on the design and development of molecular-targeted, small molecule drugs to treat cancer.

Website: https://karustherapeutics.com/

Twitter/X: karustx

Top Investors: IP Group, Novo Holdings, SV Health Investors, New Leaf Venture Partners, Esperante Ventures

Description:

Karus is an emerging pharmaceutical company whose R&D activities are focused on the design and development of innovative, molecular-targeted, small molecule drugs to treat immune/inflammatory disorders and cancer.

Total Funding Amount:

$14.8M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Chilworth, Hampshire, United Kingdom

Founded Date:

2005-01-01

Contact Email:

info(AT)karustherapeutics.com

Founders:

Paul Townsend

Number of Employees:

11-50

Last Funding Date:

2016-05-05

IPO Status:

Private

Industries:

© 2025 bioDAO.ai